An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Davis, Ian D

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Jun 2007 - 3630-6 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1078-0432

10.1158/1078-0432.CCR-07-0410 doi


Adult
Aged
Antineoplastic Agents--administration & dosage
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Female
Granzymes--drug effects
Humans
Interleukin-2 Receptor alpha Subunit--blood
Interleukins--administration & dosage
Male
Maximum Tolerated Dose
Melanoma--drug therapy
Middle Aged
Perforin
Pore Forming Cytotoxic Proteins--drug effects
Recombinant Proteins--administration & dosage
Interleukin-21